There is consistent rise in the hemophilia treatment market is owing to several factors which have led to advancement in treatment of hemophilia over the years. One of the pivotal factor which led to the increase in hemophilia treatment market is the rise in prevalence of hemophilia cases worldwide. According to the Center for Disease Control and Prevention (CDC), hemophilia occurs in approximately 1 in 5000 live births and approximately 20,000 individuals in the United States are suffering from Hemophilia. Moreover, the growing technological advancements along with increase in government funding have led to the development of several new products for treatment of hemophilia which also boosts the growth of this market. Additionally owing to the large financial cost of care related to hemophilia, several government agencies have reimbursement for hemophilia treatment which has led to substantial growth of the global hemophilia treatment market between 2019 and 2026. However the elevated cost for the treatment of hemophilia and limited access to treatment confined to specific regions, have led to hamper the market growth.
Market Industry Reports (MIR) has published a new report titled “Hemophilia Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2026.” According to the report, the global hemophilia treatment market is estimated to be over US$ 11.2 Bn in 2018. It is anticipated to grow at 5.7% CAGR from 2019 to 2026.
Get sample copy of Hemophilia Treatment Market:
Some of the prominent players in the Hemophilia Treatment Market:
Baxter, Grifols S.A., CSL Ltd., Novo Nordisk A/S, Kedrion S.p.A, Pfizer Inc., Bayer AG, Sanofi, Takeda, Octapharma
Hemophilia is an inherited bleeding disorder in which a person lacks or has low levels of specific proteins called clotting factors which leads to improper blood clotting hence causing excessive bleeding. Treatment of such bleeding disorders is very expensive. The clotting factor concentrates are considered to be one of the most expensive drugs in the market hence financial aspects are an important consideration for treating hemophilia. Favorable reimbursement offered by government agencies, pharmaceutical companies and private players in specific regions has contributed in assisting in financial burdens which are faced for treating hemophilia. Hemophilia a genetic disease which is costly to treat, receives 100% reimbursement coverage in most developed world and some developing countries. For instance in England, all services and treatments for hemophilia are paid directly by NHS England through specialized services.
As a standard protocol at MIR, all research assignments go through the following rigorous processes.
- Secondary Research
- Primary Research
- Market Size Estimation & Forecasting
- Data Validation & Triangulation
- Report Generation
Have any query? Inquiry about report at:
Table of Contents
- Market Definition
- Market Classification
- Geographic Scope
- Years Considered for the Study: Historical Years – 2017 & 2018; Base Year – 2019; Forecasted Years – 2020 to 2030
- Currency Used
- RESEARCH METHODOLOGY
- Research Framework
- Data Collection Technique
- Data Sources
- Market Estimation Methodology
- Data Validation and Triangulation
- ABSTRACT OF THE STUDY
- MARKET DYNAMICS ASSESSMENT
Buy this report @ https://www.marketindustryreports.com/checkout/109
About Market Industry Reports
Market Industry Reports is a global leader in market measurement & advisory services, Market Industry Reports is at the forefront of innovation to address the worldwide industry trends and opportunities. We identified the caliber of market dynamics & hence we excel in the areas of innovation and optimization, integrity, curiosity, customer and brand experience, and strategic business intelligence through our research.
We continue to pioneer state-of-the-art approach in research & analysis that makes complex world simpler to stay ahead of the curve. By nurturing the perception of genius and optimized market intelligence we bring proficient contingency to our clients in the evolving world of technologies, megatrends and industry convergence. We empower and inspire Vanguards to fuel and shape their business to build and grow world-class consumer products.
Phone: + 91 8956767535